Pharvaris N.V. (PHVS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2020, filed Apr 29, 2021. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PHVS SEC filings page.
This page shows Pharvaris N.V. (PHVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Pharvaris N.V. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Pharvaris N.V. reported -$26.0M in net income in fiscal year 2020. This represents a decrease of 223.7% from the prior year.
Not reported for fiscal year 2020.
Not reported for fiscal year 2020.
Not reported for fiscal year 2020.
Cash & Balance Sheet
Not reported for fiscal year 2020.
Not reported for fiscal year 2020.
Not reported for fiscal year 2020.
Margins & Returns
None of these metrics is reported for fiscal year 2020.
Capital Allocation
None of these metrics is reported for fiscal year 2020.
PHVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted).
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Pharvaris N.V. PHVS | FY2020 | N/A | -$26.0M | N/A | $2.7B | — |
| Ardelyx, Inc. ARDX | FY2025 | $407.3M | -$62.0M | -15.2% | $934.6M | 45/100 |
| Edgewise Therapeutics, Inc. EWTX | FY2025 | N/A | -$168K | N/A | $4.7B | — |
| Biohaven Ltd. BHVN | FY2025 | N/A | -$738.8M | N/A | $1.9B | — |
| Mannkind Corporation MNKD | FY2025 | $349.0M | $5.9M | 1.7% | $1.2B | 51/100 |
| Cidara Therapeutics, Inc. CDTX | FY2024 | $1.3M | -$169.8M | N/A | $7.0B | 49/100 |
Where Pharvaris N.V. Ranks
Frequently Asked Questions
Is Pharvaris N.V. profitable?
No, Pharvaris N.V. (PHVS) reported a net income of -$26.0M in fiscal year 2020.
What is Pharvaris N.V.'s P/E ratio?
Pharvaris N.V. (PHVS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2020). The market capitalization is $2.7B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Pharvaris N.V.'s price-to-sales ratio?
Pharvaris N.V. (PHVS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.7B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.